What to look Forward to in 2025 Research/Science 1/26/2025
Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.
View this post in the Community →
Similar Community Posts Join
5 / 11 resultscommunity I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
community FOL005 claims it's better than Finasteride and Minoxidil.
FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.
community Status update on upcoming treatments
Current treatments like finasteride, minoxidil, and derma rolling are considered the best for hair loss, while new treatments such as GT20029, PP405, and others are in various trial phases with results expected in the coming years. There is cautious optimism about the affordability and effectiveness of these upcoming treatments.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
community When will Breezula, SM04554, Follica FOL-004, follicum FOL-005 arrive in Canada?
The conversation is about the availability of hair loss treatments Breezula, SM04554, Follica FOL-004, and Follicum FOL-005 in Canada after FDA approval, including potential delays, loopholes for obtaining them, and insurance coverage.
Related Research
6 / 24 resultsresearch Identification of Novel Potential Therapeutic Targets by Comparative Transcriptomic Profiling of Physiological and Pathological Skin Wounds Ex Vivo
Combining certain treatments, including FOL005, may improve healing of difficult wounds.
research Identification of an Osteopontin-Derived Peptide That Binds Neuropilin-1 and Activates Vascular Cells
FOL-026 peptide can help repair blood vessels and promote growth, offering potential treatment for vascular diseases.
research A Novel Microparticle-Based Formulation for Topical Delivery of FOL-005, a Small Peptide
The new skin cream with FOL-005 safely promotes hair growth and is stable and user-friendly.
research Mutational Landscape of Extramammary Paget Disease
The document concludes that ERBB2 mutations are common in extramammary Paget disease and may respond to systemic treatments like cancer immunotherapy.
research FGF7-Dependent Inhibition of Human Hair Growth by an Osteopontin-Derived Peptide: A Novel Solution for Hirsutism and Hypertrichosis
A new peptide, FOL-005, may help treat excessive hair growth by reducing a hair growth promoter, FGF7.
research Osteopontin Regulatory Functions in the Hair Follicle Open a Therapeutic Approach for Hypertrichosis
FOL-005 peptide may help treat excessive hair growth safely.